NCT06482749 Repetitive Transcranial Magnetic Stimulation and Postoperative Neurocognitive Recovery
| NCT ID | NCT06482749 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Older Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 568 participants |
| Start Date | 2025-07-28 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 568 participants in total. It began in 2025-07-28 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with preoperative cognitive impairment are at increased risks of delayed neurocognitive recovery (DNR) and postoperative neurocognitive disorder (POCD). Repetitive transcranial magnetic stimulation (rTMS) has been used to improve cognitive function in patients with cognitive impairement. This trial is designed to compare the effects of rTMS versus sham intervention on postoperative neurocognitive function in patients with preoperative cognitive impairment.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥65 years; 2. Patients with preoperative mild to moderate cognitive impairment, defined as 9\<Montreal Cognitive Assessment (MoCA)\<26; 3. Scheduled for elective non-cardiac surgery under general anesthesia, with an expected surgical duration of \>2 hours; 4. Expected to stay in hospital for at least 5 days after surgery. Exclusion Criteria: 1. Left-handed; 2. Primary school education level or below; 3. Comorbid diseases including mental illness, intellectual disability, auditory and visual dysfunction, language impairment, severe neurological disorders, or other diseases that impede the completion of evaluation; 4. Neurosurgery; 5. Presence of contraindications to rTMS treatment, including epilepsy, pregnant or lactating women, or with a metal or electric implanted device (e.g., deep brain stimulator, ventriculoperitoneal shunt, aneurysm clip, pacemaker, cochlear implant, or surgical staples on the scalp); 6. Other situations that are deemed unsuitable for inclusion in the study.
Contact & Investigator
Dong-Xin Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT06482749 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Older Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06482749 currently recruiting?
Yes, NCT06482749 is actively recruiting participants. Contact the research team at wangdongxin@hotmail.com for enrollment information.
Where is the NCT06482749 trial being conducted?
This trial is being conducted at Beijing, China, Shenzhen, China, Xi'an, China.
Who is sponsoring the NCT06482749 clinical trial?
NCT06482749 is sponsored by Peking University First Hospital. The principal investigator is Dong-Xin Wang, MD, PhD at Peking University First Hospital. The trial plans to enroll 568 participants.